- Snapdragon Chemistry and Atinary Technologies has announced a strategic collaboration to enhance the development of active pharmaceutical ingredients (APIs).
- The integration of their technologies aims to improve product yield by up to 18% and reduce costs by 22%.
Snapdragon Chemistry, a Cambrex company and Atinary Technologies, known for its no-code AI platform SDLabs, has formed a strategic partnership. This collaboration integrates Snapdragon’s proprietary LabOS software with Atinary’s SDLabs to create a fully automated, AI-driven medium-throughput Solid-Phase Oligonucleotide Synthesizer (SPOS).
The collaboration aims to enhance process optimization in pharmaceutical R&D. Initial results indicate that the AI-driven approach can achieve an 18% increase in product yield and reduce costs by 22% compared to traditional methods. This improvement highlights the potential of AI technologies in expediting complex chemistry processes.
Dr. Hermann Tribukait, Co-Founder and CEO of Atinary Technologies, stated, “Our work with Snapdragon showcases the power of our AI and data-driven process to solve complex chemistry and molecular discovery challenges.” Meanwhile, Dr. Eric Fang, General Manager of Snapdragon Chemistry, expressed enthusiasm about expanding their technological capabilities through this partnership.
“We are excited about the opportunity to expand Snapdragon’s technological capability by integrating Atinary’s AI technology in our process R&D activities,” said Dr. Eric Fang, General Manager of Snapdragon Chemistry. “We believe that our combined expertise and shared vision for accelerated innovation will lead to significant advancements and added value for our customers, streamlining and expediting drug development pipelines and R&D portfolios.”
Overview of outsourcing trends 
